articleTop 1% cited

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

The Lancet Oncology · 2015 · Vol. 16(3) · pp. 257–265

Naiyer A. Rizvi✉(Memorial Sloan Kettering Cancer Center)Julien Mazières(Hôpital Larrey)David Planchard(Institut Gustave Roussy)Thomas E. Stinchcombe(University of North Carolina at Chapel Hill)Grace K. Dy(Roswell Park Comprehensive Cancer Center)Scott Antonia(Moffitt Cancer Center)Leora Horn(Vanderbilt-Ingram Cancer Center)H. Léna(Centre Hospitalier Universitaire de Rennes)Elisa MinenzaB. Mennecier(Hôpital Civil, Strasbourg)Gregory A. Otterson(The Ohio State University)Luis T. Campos(Hematology Oncology Consultants)David R. Gandara(University of California, Davis)Benjamin Levy(Mount Sinai Beth Israel)Suresh Nair(Lehigh Valley Hospital-Pocono)Gérard Zalcman(Centre Hospitalier Universitaire de Caen Normandie)Jürgen WolfPierre‐Jean Souquet(Hospices Civils de Lyon)Editta BaldiniFederico Cappuzzo(Ospedale di Livorno)C. Chouaïd(Hôpital Intercommunal de Créteil)Afshin Dowlati(University Hospitals of Cleveland)Rachel E. Sanborn(Providence Portland Medical Center)Ariel López-Chávez(University of Miami)Christian Grohé(Evangelische Lungenklinik Berlin)Rudolf M. Huber(German Center for Lung Research)Christopher Harbison(Bristol-Myers Squibb (United States))Christine Baudelet(Bristol-Myers Squibb (United States))Brian Lestini(Bristol-Myers Squibb (United States))Suresh S. Ramalingam(Emory University)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research Lung Cancer Treatments and MutationsNivolumabMedicineInternal medicineRefractory (planetary science)PneumonitisClinical endpointLung cancerAdverse effectPembrolizumabResponse Evaluation Criteria in Solid Tumors

MeSH terms

NivolumabAgedAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Administration ScheduleEuropeFemaleHumansInfusions, IntravenousLung NeoplasmsMaleMiddle AgedRisk FactorsTime Factors

Citations

1,421

FWCI

107.19

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer